Dosing begins in trial testing Enhertu for ovarian cancer
Dosing has begun in a Phase 3 clinical trial testing Enhertu (trastuzumab deruxtecan) as a maintenance treatment for certain people with ovarian cancer. The…
News
CLN-049 now has FDA fast track designation for hard-to-treat AML
The U.S. Food and Drug Administration (FDA) has granted fast track designation to the experimental medicine CLN-049, which is being developed as a potential treatment…
Oncolytics to test immunotherapy against aggressive pancreatic cancer
Oncolytics Biotech has cleared a significant hurdle in the U.S. to advance its unique viral immunotherapy, pelareorep, to a pivotal Phase 3 trial for…
New therapy DT2216 tackles tough-to-treat ovarian cancer
A new experimental therapy, DT2216, has begun testing in a clinical trial for people with hard-to-treat ovarian cancer, a significant step forward announced by…
California myeloma clinic reports ‘unprecedented’ patient survival
Most myeloma patients who started treatment at the Berenson Cancer Center — a clinic in California that specializes in myeloma care — lived…
New center promotes advocacy for gynecological cancer patients
The Ovarian Cancer Research Alliance (OCRA) launched a project to push lawmakers to enact legislation that will improve the lives of people affected by…
FDA clears Thermo Fisher EXTENT system for myeloma diagnosis
Thermo Fisher Scientific has received U.S. Food and Drug Administration (FDA) clearance for its EXENT System, an automated test that helps doctors diagnose multiple…
New ‘powerful’ lab test will help researchers explore blood cancer
Mission Bio has debuted a new laboratory test that enables researchers to simultaneously detect alterations in the genetic code and changes in genetic activity…
Case: Growth on pancreas shows estrogen link to pancreatic cancer
Changes in how cells respond to the hormone estrogen may underlie the development of certain forms of pancreatic cancer. That’s according to findings from…
Glioma trial of intranasal therapy NEO100 fills all patient slots
Neonc Technologies has completed enrollment for its Phase 2a clinical trial of NEO100, an intranasal treatment for high-grade glioma, the company announced. This follows…
